The DOI matches its Crossref record; 223 of the 223 references it cites were found in a registry or an index.
The MYC oncogene — the grand orchestrator of cancer growth and immune evasion
Open accessAbstract
The MYC proto-oncogenes encode a family of transcription factors that are among the most commonly activated oncoproteins in human neoplasias. Indeed, MYC aberrations or upregulation of MYC-related pathways by alternate mechanisms occur in the vast majority of cancers. MYC proteins are master regulators of cellular programmes. Thus, cancers with MYC activation elicit many of the hallmarks of cancer required for autonomous neoplastic growth. In preclinical models, MYC inactivation can result in sustained tumour regression, a phenomenon that has been attributed to oncogene addiction. Many therapeutic agents that directly target MYC are under development; however, to date, their clinical efficacy remains to be demonstrated. In the past few years, studies have demonstrated that MYC signalling can enable tumour cells to dysregulate their microenvironment and evade the host immune response. Herein, we discuss how MYC pathways not only dictate cancer cell pathophysiology but also suppress the host immune response against that cancer. We also propose that therapies targeting the MYC pathway will be key to reversing cancerous growth and restoring antitumour immune responses in patients with MYC -driven cancers. The MYC proto-oncogenes are among the most commonly activated proteins in human cancer, yet the clinical efficacy of MYC-targeted agents remains to be demonstrated. The authors of this Review describe how activation of the MYC pathway affects cancer cells as well as the tumour microenvironment and propose strategies for the therapeutic targeting of MYC -driven cancers. The MYC oncogene is activated in the vast majority of cancers by genetic, epigenetic or post-translational mechanisms. In preclinical models, inactivation of MYC can result in sustained tumour regression owing to oncogene addiction. MYC activation drives cancer progression through mechanisms involving either the cell-intrinsic acquisition of hallmarks of cancer or dysregulation of the tumour microenvironment and host immune responses. MYC leads to cancer initiation and maintenance by regulating the host immune system through mechanisms involving immune checkpoints, specific receptors and secreted cytokines. Currently, no direct inhibitors of MYC are approved; however, many therapeutic agents targeting MYC are under development. We propose that therapies targeting the MYC pathway will be key to reversing cancerous growth and restoring antitumour immune responses in patients with MYC-driven cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–223 of 223
Vartuli, R. L., Zhou, H., Zhang, L., Powers, R. K., Klarquist, J. S., Rudra, P., Vincent, M. Y., Ghosh, D., Costello, J. C., Kedl, R. M., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96784 · Cited by 44
Inhibiting MYC binding to the E-box DNA motif by ME47 decreases tumour xenograft growth
Lustig, L. C., Dingar, D. D., Tu, W. B., Lourenco, C., Kalkat, M., Inamoto, I., Ponzielli, R., Chan, W. C. W., Shin, J. A., & Penn, L. Z. (2017) · Oncogene · doi:10.1038/onc.2017.275 · Cited by 41
The biology of multiple myeloma
Drach, J. W., Kaufmann, H., Urbauer, E., Schreiber, S., Ackermann, J., & Huber, H. P. (2000) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s004320050011 · Cited by 38
Dhanasekaran, R., Park, J., Yevtodiyenko, A., Bellovin, D. I., Adam, S. J., Rajan, A., Gabay, M., Fernando, H., Arzeno, J., Arjunan, V., et al. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.07.008 · Cited by 35
Self-citationThe Myc and Ras Partnership in Cancer: Indistinguishable Alliance or Contextual Relationship?
Mahauad‐Fernandez, W. D., & Felsher, D. W. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0787 · Cited by 32
Self-citationOncogene withdrawal engages the immune system to induce sustained cancer regression
Casey, S. C., Li, Y., Fan, A. C., & Felsher, D. W. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-2-24 · Cited by 30
Self-citationThe biology of multiple myeloma
Drach, J., Kaufmann, H., Urbauer, E., Schreiber, S., Ackermann, J., & Huber, H. (2000) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/pl00021279 · Cited by 29
MNT and Emerging Concepts of MNT‐MYC Antagonism
Yang, G., & Hurlin, P. J. (2017) · Genes · doi:10.3390/genes8020083 · Cited by 29
Convergence of Cancer Metabolism and Immunity: an Overview
Dang, C. V., & Kim, J. (2017) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2017.194 · Cited by 29
Modelling the MYC-driven normal-to-tumour switch in breast cancer
Lourenco, C., Kalkat, M., Houlahan, K. E., Melo, J. D., Longo, J., Done, S. J., Boutros, P. C., & Penn, L. Z. (2019) · Disease Models & Mechanisms · doi:10.1242/dmm.038083 · Cited by 26
Krüger, K., Geist, K., Stuhldreier, F., Schumacher, L., Blümel, L., Remke, M., Wesselborg, S., Stork, B., Klöcker, N., Bormann, S., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.05.011 · Cited by 24
Myc and Ras, the Bonnie and Clyde of immune evasion
Casacuberta‐Serra, S., & Soucek, L. (2018) · Translational Cancer Research · doi:10.21037/tcr.2018.03.09 · Cited by 22
Tran, D., Verma, K., Ward, K. A., Diaz, D., Kataria, E., Torabi, A., Almeida, A., Malfoy, B., Stratford, E. W., Mitchell, D., et al. (2015) · American Journal Of Pathology · doi:10.1016/j.ajpath.2014.11.024 · Cited by 20
Edelmann, J., Tausch, E., Landau, D. A., Robrecht, S., Bahlo, J., Fischer, K., Fink, A. M., Bloehdorn, J., Holzmann, K., Böttcher, S., et al. (2016) · Leukemia · doi:10.1038/leu.2016.317 · Cited by 20
Long path to MYC inhibition approaches clinical trials
Villanueva, M. T. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0141-9 · Cited by 16
Seton-Rogers, S. E. (2018) · Nature reviews. Cancer · doi:10.1038/nrc.2018.5 · Cited by 15
A mathematical model of tumor regression and recurrence after therapeutic oncogene inactivation
Hori, S. S., Tong, L., Swaminathan, S., Liebersbach, M., Wang, J., Gambhir, S. S., & Felsher, D. W. (2021) · Scientific Reports · doi:10.1038/s41598-020-78947-2 · Cited by 12
Self-citationFriesen, L., Gu, B., & Kim, C. H. (2020) · Mucosal Immunology · doi:10.1038/s41385-020-0311-9 · Cited by 10
Long path to MYC inhibition approaches clinical trials
Villanueva, M. T. (2019) · Nature Reviews Drug Discovery · doi:10.1038/d41573-019-00055-2 · Cited by 8
Dang, C. V., & Eisenman, R. N. (2014) · Medical Entomology and Zoology · Cited by 6
Immune Cell Activation: Stimulation, Costimulation, and Regulation of Cellular Activation
Kapur, S., & Pal, A. K. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.81568 · Cited by 5
Double boost for mRNA cancer vaccines
Villanueva, M. T. (2019) · Nature Reviews Drug Discovery · doi:10.1038/d41573-019-00192-8 · Cited by 3
MYC Regulation of Metabolism and Cancer
Gouw, A. M., Hsieh, A. L., Stine, Z. E., & Dang, C. V. (2015) · Springer eBooks · doi:10.1007/978-3-7091-1824-5_5 · Cited by 2
Self-citation
Cited by
Breast cancer: pathogenesis and treatments
Xiong, X., Zheng, L.-W., Ding, Y., Chen, Y.-F., Cai, Y.-W., Wang, L.-P., Huang, L., Liu, C.-C., Shao, Z.-M., & Yu, K.-D. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02108-4 · Cited by 958
Therapeutic targeting of “undruggable” MYC
Llombart, V., & Mansour, M. R. (2022) · eBioMedicine · doi:10.1016/j.ebiom.2021.103756 · Cited by 472
Immunologic tumor microenvironment modulators for turning cold tumors hot
Khosravi, G., Mostafavi, S., Bastan, S., Ebrahimi, N., Gharibvand, R. S., & Eskandari, N. (2024) · Cancer Communications · doi:10.1002/cac2.12539 · Cited by 364
Cancer immune evasion, immunoediting and intratumour heterogeneity
Roerden, M., & Spranger, S. (2025) · Nature Reviews Immunology · doi:10.1038/s41577-024-01111-8 · Cited by 265
PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)
He, M., Cao, C., Ni, Z., Liu, Y., Song, P., Hao, S., He, Y., Sun, X., & Rao, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00999-9 · Cited by 283
Metadata
- Authors
- Dhanasekaran, R., Deutzmann, A., Mahauad-Fernandez, W. D., Hansen, A. S., Gouw, A. M., & Felsher, D. W.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2021-09-10
- Volume
- 19
- Issue
- 1
- Pages
- 23-36
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W3196329163
- Cited by
- 986
- References
- 223
- FWCI
- 19.69
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.